抖圈官网

leo_gymc
gx_imgmc
20191105112725_5dc0ec1d7126c 20191106104659_5dc23423ae2fc

Products&Pipeline

Pipeline

Product and Pipeline
Indication
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Dorzagliatin
T2D-Drug Na?ve
l_b3_tabqq
T2D-Metformin Tolerated
l_b3_tabqq
RWE study for Diabetes Remission
l_b3_tabqq
MODY-2
l_b3_tabqq
Diabetes prevention
l_b3_tabqq
Frailty
l_b3_tabqq
Early AD
l_b3_tabqq
CFRD
l_b3_tabqq
Dorzagliatin and Metformin FDC
T2D
l_b3_tabqq
Dorzagliatin add on to Insulin
Insulin sparing in T2D
l_b3_tabqq
2nd Generation GKA
Metabolic Disease
l_b3_tabqq
Dorzagliatin add on to GLP-1 RAs
T2D and Obesity
l_b3_tabqq
Dorzagliatin + small molecule GLP-1 RAs
T2D and Obesity
l_b3_tabqq
Dorzagliatin + THR-β agonists
T2D and MASH/MASLD
l_b3_tabqq
Dorzagliatin + PanPPAR agnoists
T2D and MASH/MASLD
l_b3_tabqq
Dorzagliatin + Empagliflozin
DKD
l_b3_tabqq
Dorzagliatin + Sitagliptin
T2D
l_b3_tabqq
mGLUR5 NAM
PD-LID
l_b3_tabqq
Drug Addiction
l_b3_tabqq
GK NAM
Metabolic Disease
l_b3_tabqq
Dorzagliatin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D-Drug Na?ve
l_b3_tabqq
T2D-Metformin Tolerated
l_b3_tabqq
RWE study for Diabetes Remission
l_b3_tabqq
MODY-2
l_b3_tabqq
Diabetes prevention
l_b3_tabqq
Frailty
l_b3_tabqq
Early AD
l_b3_tabqq
CFRD
l_b3_tabqq
Dorzagliatin and Metformin FDC
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D
l_b3_tabqq
Dorzagliatin add on to Insulin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Insulin sparing in T2D
l_b3_tabqq
2nd Generation GKA
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Metabolic Disease
l_b3_tabqq
Dorzagliatin add on to GLP-1 RAs
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and Obesity
l_b3_tabqq
Dorzagliatin + small molecule GLP-1 RAs
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and Obesity
l_b3_tabqq
Dorzagliatin + THR-β agonists
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and MASH/MASLD
l_b3_tabqq
Dorzagliatin + PanPPAR agnoists
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D and MASH/MASLD
l_b3_tabqq
Dorzagliatin + Empagliflozin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
DKD
l_b3_tabqq
Dorzagliatin + Sitagliptin
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
T2D
l_b3_tabqq
mGLUR5 NAM
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
PD-LID
l_b3_tabqq
Drug Addiction
l_b3_tabqq
GK NAM
Discovery
(Pre-clinical-Phase II)
Development
(Phase III)
Commercialization
Metabolic Disease
l_b3_tabqq
Focus Us
l_foot_lyixc
20191104104225_5dbf9011aa5f3
l_foot_wx
20190929160723_5d90663b11c8b
Copyright ? 2026  Hua Medicine (Shanghai) Ltd.    沪网药械信备字【2026】000123号
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
l_foot_gotop
Search
l_ss_guanbi
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
【网站地图】